TY - JOUR
T1 - Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.
AU - Fotino, Carmen
AU - Ricordi, Camillo
AU - Lauriola, Vincenzo
AU - Alejandro, Rodolfo
AU - Pileggi, Antonello
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2010
Y1 - 2010
N2 - The bone marrow is an invaluable source of adult pluripotent stem cells, as it gives rise to hematopoietic stem cells, endothelial progenitor cells, and mesenchymal cells, amongst others. The use of bone marrow-derived stem cell (BMC) transplantation (BMT) may be of assistance in achieving tissue repair and regeneration, as well as in modulating immune responses in the context of autoimmunity and transplantation. Ongoing clinical trials are evaluating the effects of BMC to preserve functional beta-cell mass in subjects with type 1 and type 2 diabetes, and to favor engraftment and survival of transplanted islets. Additional trials are evaluating the impact of BMT (i.e., mesenchymal stem cells) on the progression of diabetes complications. This article reviews the progress in the field of BMC for the treatment of subjects with insulin-dependent diabetes, and summarizes clinical data of pilot studies performed over the last two decades at our research center by combining allogeneic islet transplantation with donor-specific BMC. Clinical data is summarized from pilot studies performed at our research center over the last two decades.
AB - The bone marrow is an invaluable source of adult pluripotent stem cells, as it gives rise to hematopoietic stem cells, endothelial progenitor cells, and mesenchymal cells, amongst others. The use of bone marrow-derived stem cell (BMC) transplantation (BMT) may be of assistance in achieving tissue repair and regeneration, as well as in modulating immune responses in the context of autoimmunity and transplantation. Ongoing clinical trials are evaluating the effects of BMC to preserve functional beta-cell mass in subjects with type 1 and type 2 diabetes, and to favor engraftment and survival of transplanted islets. Additional trials are evaluating the impact of BMT (i.e., mesenchymal stem cells) on the progression of diabetes complications. This article reviews the progress in the field of BMC for the treatment of subjects with insulin-dependent diabetes, and summarizes clinical data of pilot studies performed over the last two decades at our research center by combining allogeneic islet transplantation with donor-specific BMC. Clinical data is summarized from pilot studies performed at our research center over the last two decades.
UR - http://www.scopus.com/inward/record.url?scp=79952278457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952278457&partnerID=8YFLogxK
U2 - 10.1900/RDS.2010.7.144
DO - 10.1900/RDS.2010.7.144
M3 - Review article
C2 - 21060973
AN - SCOPUS:79952278457
VL - 7
SP - 144
EP - 157
JO - The review of diabetic studies : RDS
JF - The review of diabetic studies : RDS
SN - 1613-6071
IS - 2
ER -